ES2153403T3 - Preparaciones farmaceuticas que contienen el factor citotoxico tumoral. - Google Patents

Preparaciones farmaceuticas que contienen el factor citotoxico tumoral.

Info

Publication number
ES2153403T3
ES2153403T3 ES94301251T ES94301251T ES2153403T3 ES 2153403 T3 ES2153403 T3 ES 2153403T3 ES 94301251 T ES94301251 T ES 94301251T ES 94301251 T ES94301251 T ES 94301251T ES 2153403 T3 ES2153403 T3 ES 2153403T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparations
tcf
preparations containing
cytotoxic factor
tumor cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94301251T
Other languages
English (en)
Inventor
Hitoshi Hayasaka
Nobuyuki Kawashima
Masatsugu Ueda
Eitaro Kumazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of ES2153403T3 publication Critical patent/ES2153403T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EN ESTA INVENCION SE PRESENTAN PREPARACIONES FARMACEUTICAS QUE CONTIENE UN FACTOR CITOTOXICO A LOS TUMORES (TCF) MUY CONCENTRADO. LAS PREPARACIONES FARMACEUTICAS DE LA PRESENTE INVENCION CONTIENEN UN TCF MUY CONCENTRADO Y AMINOACIDOS BASICOS O SUS SALES, O UNA SAL ORGANICA O INORGANICA COMO SOLUBILIZADOR. LAS COMPOSICIONES RESULTANTES DESCRITAS EN LA PRESENTE INVENCION DISUELVEN EL TCF A CONCENTRACIONES ELEVADAS DE 10 MG/ML O SUPERIORES BAJO CONDICIONES MAS O MENOS NEUTRAS O ISOTONICAS. LAS COMPOSICIONES RESULTANTES SON ESTABLES Y ADECUADAS PARA PREPARACIONES DE INYECCIONES.
ES94301251T 1993-02-23 1994-02-22 Preparaciones farmaceuticas que contienen el factor citotoxico tumoral. Expired - Lifetime ES2153403T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP05782693A JP3552240B2 (ja) 1993-02-23 1993-02-23 高濃度ｔｃｆ製剤

Publications (1)

Publication Number Publication Date
ES2153403T3 true ES2153403T3 (es) 2001-03-01

Family

ID=13066735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94301251T Expired - Lifetime ES2153403T3 (es) 1993-02-23 1994-02-22 Preparaciones farmaceuticas que contienen el factor citotoxico tumoral.

Country Status (11)

Country Link
US (1) US5510327A (es)
EP (1) EP0612530B1 (es)
JP (1) JP3552240B2 (es)
KR (1) KR100271671B1 (es)
AT (1) ATE197404T1 (es)
AU (1) AU678421B2 (es)
CA (1) CA2116192C (es)
DE (1) DE69426244T2 (es)
DK (1) DK0612530T3 (es)
ES (1) ES2153403T3 (es)
ZA (1) ZA941198B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674871B2 (en) * 1992-07-16 1997-01-16 Atlas Pharmaceuticals Inc. Blood coagulation normalizer containing TCF-II as active ingredient
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
ATE359809T1 (de) * 1999-05-31 2007-05-15 Mitsubishi Chem Corp Gefriergetrocknete hgf-präparationen
GB9921960D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and amino acids
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CN105168127A (zh) * 2015-10-23 2015-12-23 广西裕源药业有限公司 一种塑瓶装氯化钠注射液的生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076701A (en) * 1975-07-29 1978-02-28 Immunology Research Foundation, Inc. Tumor complement fraction recovery method and product
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
ATE178354T1 (de) * 1990-07-13 1999-04-15 Snow Brand Milk Products Co Ltd Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung

Also Published As

Publication number Publication date
CA2116192C (en) 2005-05-10
EP0612530A3 (en) 1995-05-10
ATE197404T1 (de) 2000-11-11
JPH06247872A (ja) 1994-09-06
AU678421B2 (en) 1997-05-29
KR100271671B1 (ko) 2000-11-15
KR950024769A (ko) 1995-09-15
CA2116192A1 (en) 1994-08-24
DK0612530T3 (da) 2001-03-05
AU5630794A (en) 1994-09-01
US5510327A (en) 1996-04-23
EP0612530B1 (en) 2000-11-08
DE69426244T2 (de) 2001-03-29
ZA941198B (en) 1994-09-20
DE69426244D1 (de) 2000-12-14
JP3552240B2 (ja) 2004-08-11
EP0612530A2 (en) 1994-08-31

Similar Documents

Publication Publication Date Title
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
ES2161290T3 (es) Derivados de quinazolina.
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
ES2079694T3 (es) Derivados de bifenilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2084944T3 (es) Amidas terapeuticas.
ES2147230T3 (es) Derivados de aminoacidos, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ES2147924T3 (es) Composicion terapeutica que comprende un antigeno o un generador in vivo de un compuesto que comprende una secuencia de aminoacidos.
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES2153367T3 (es) Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen.
ES8707974A1 (es) Procedimiento para la obtencion de un peptido
ES2060616T3 (es) Sales organicas de derivados de fisostigmina.
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
ES8404332A1 (es) Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos
MX9303466A (es) Derivados de bifenilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
DOP2024000269A (es) Composiciones y uso de la tirzepatida
EP0612530A3 (en) A pharmaceutical composition containing cytotoxic factor for tumors.
ES2103486T3 (es) Medicamentos que contienen acidos difosfonicos y sus sales.
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
ES2093752T3 (es) Complejos de hierro que contienen conalbumina y sus derivados.
ES2052901T3 (es) Un metodo para preparar derivados e isomeros de 4,5,6,7-tetrahidroisotiazolo(4,5-c)piridinas.
ES2056849T3 (es) Heteroalquilen-quinolinaminas condensadas, un procedimiento y productos intermedios para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612530

Country of ref document: ES